Literature DB >> 11210400

Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation.

G Sathyan1, W Hu, S K Gupta.   

Abstract

The effect of food on the pharmacokinetics of 15 mg oxybutynin XL was evaluated in a single-dose, randomized, crossover, open-label study in healthy volunteers. A validated, stereospecific, high-performance liquid chromatography assay was used to simultaneously determine the plasma concentrations of R- and S-oxybutynin and active metabolite R- and S-desethyloxybutynin. The mean AUC and Cmax values for each of the four analytes in the fed treatment were within +/- 20% of the fasting treatment values. The 90% confidence intervals for the treatment ratios (fed/fasted) for log-transformed Cmax and AUCinf values for the drug isomers and AUCinf values for the metabolite isomers were all within the 80% to 125% range. Only the ranges for the Cmax values for R- and S-desethyloxybutynin were slightly wider but were well within the 70% to 143% criteria recommended for Cmax when comparing effect of food. Lack of effect of food on oxybutynin XL is consistent with the previous observation that the osmotically controlled formulations are nearly insensitive to the gastrointestinal environment, including food. Oxybutynin XL was well tolerated, and the safety results were comparable whether administered alone or with food. In conclusion, oxybutynin XL administration does not require any caution to be exercised regarding food.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11210400     DOI: 10.1177/00912700122010014

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

Review 1.  Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?

Authors:  Martin C Michel; Sharath S Hegde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11       Impact factor: 3.000

2.  The effects of reformulation: improved therapeutic index.

Authors:  Scott MacDiarmid; Bobby W Sandage; Bimal K Malhotra
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

3.  Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.

Authors:  Gayatri Sathyan; Roger R Dmochowski; Rodney A Appell; Cindy Guo; Suneel K Gupta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Advances in drug delivery: improved bioavailability and drug effect.

Authors:  Roger R Dmochowski; David R Staskin
Journal:  Curr Urol Rep       Date:  2002-12       Impact factor: 2.862

7.  Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.

Authors:  Gayatri Sathyan; Emily Xu; John Thipphawong; Suneel K Gupta
Journal:  BMC Clin Pharmacol       Date:  2007-02-02

Review 8.  A short review of drug-food interactions of medicines treating overactive bladder syndrome.

Authors:  Paweł Paśko; Tomasz Rodacki; Renata Domagała-Rodacka; Danuta Owczarek
Journal:  Int J Clin Pharm       Date:  2016-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.